Diane V. Havlir, MD

Diane Havlir
Global Health Sciences Faculty Affiliate

Phone: 415-476-4082 ext. 400
UCSF Box: 0874
Email: dhavlir@php.ucsf.edu
UCSF Profile

Project Sponsor Location(s) Topics Start End
SEARCH (Sustained East Africa Research in Community Health) Study in Kenya and Uganda/ Gates Bill & Melinda Gates Foundation Kenya; Uganda HIV/AIDS, Tuberculosis, Malaria, Cardiovascular Disease, Diabetes
Novel Strategies to Prevent Malaria and Improve Maternal-Child Health in Africa (PROMOTE) NIH National Institute of Child Health and Human Development Uganda HIV/AIDS, Malaria, Pharmacology and Drug Treatment, Women's Health, Pediatrics, Newborn and Infant Health
Getting to Zero Coordinator/ SFPHF San Francisco Public Health Foundation United States HIV/AIDS
AIDS Clinical Trials Group: REPRIEVE Trial Ancillary Study Brigham and Women's Hospital United States HIV/AIDS, Cardiovascular Disease
Training in HIV Translational Research NIH National Institute of Allergy and Infectious Disease United States Training and Capacity Building
Reducing Failure-to-Initiate ART: Streamlined ART Start NIH National Institute of Allergy and Infectious Disease Uganda HIV/AIDS, Access or Barriers to Care, Implementation and Behavioral Science, Engagement in Care
AIDS Clinical Trials Group: REPRIEVE Trial (A5332 and A5333s) Massachusetts General Hospital United States HIV/AIDS, Cardiovascular Disease
Effect of low dose methotrexate on endothelial function and inflammation in HIV - A5314 Brigham and Women's Hospital United States HIV/AIDS, Pharmacology and Drug Treatment
AIDS Clinical Trials Group; Protocol Funds Brigham and Women's Hospital United States HIV/AIDS
AIDS Clinical Trial Group Network- Protocol Funding Agreement (Core Funding) Brigham and Women's Hospital United States HIV/AIDS
Heals Endowment Fund at the East Bay Community Foundation East Bay Community Foundation United States HIV/AIDS
Reducing Failure-to-Initiate ART: Streamlined ART Start Strategy (START) NIH National Institute of Allergy and Infectious Disease Uganda HIV/AIDS
Therapeutic Strategies for HIV Disease NIH National Institute of Allergy and Infectious Disease Uganda HIV/AIDS
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Africa (III) Abbott Laboratories Uganda HIV/AIDS, Malaria
Task Order A5303: Trial to Determine the Bone, Immunologic, Virologic, and Neurocognitive Effects of a Novel Maraviroc-Containing Antiretroviral Regimen in Treatment-Naive Patients Infected with R5-Tropic HIV-1 Social & Scientific Systems, Inc. Uganda HIV/AIDS, Pharmacology and Drug Treatment
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Uganda (II) Abbott Laboratories Uganda HIV/AIDS
UCSF HIV Clinical Trials Unit NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
AIDS Clinical Trial Group (ACTG) Tuberculosis TSG Services Brigham and Women's Hospital United States HIV/AIDS, Tuberculosis
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and Uninfected Pulmonary Tuberculosis Suspects Brigham and Women's Hospital United States HIV/AIDS, Tuberculosis
AIDS Clinical Trial Research Group (ACTG), Studies: A5306, A5254, A5298 Brigham and Women's Hospital Uganda HIV/AIDS, Opportunistic Infection, Tuberculosis, Oral Health
Productive and Latent HIV Infection in Gut Mucosal Reservoirs Northern California Institute for Research and Education, Inc. (NCIRE) United States HIV/AIDS
Novel Strategies to Prevent Malaria and Improve HIV Outcomes in Africa (I) NIH National Institute of Child Health and Human Development Uganda HIV/AIDS, Malaria
AIDS Research and Services at SF General Hospital East Bay Community Foundation United States HIV/AIDS, Engagement in Care, Treatment Adherence, Risk Reduction and Prevention
Study of Three NNNRTI-Sparing Antiretroviral Regimens for Treatment-Naive HIV-1-Infected Volunteers (ACTG A5257) Social & Scientific Systems, Inc. Puerto Rico HIV/AIDS, Pharmacology and Drug Treatment
Cardiovascular, Anthropometric, and Skeletal Effects of ART Initiation with FTC/TDF plus ATV/r: Metabolic Substudy of A5257 (ACTG A5260s) Social & Scientific Systems, Inc. United States HIV/AIDS
Trial of Raltegravir Plus Darunavir/Ritonavir for Treatment-Naive HIV-1-Infected Subjects (ATCG A5262) Social & Scientific Systems, Inc. United States HIV/AIDS, Pharmacology and Drug Treatment
Task Order A5280: A Prospective, Randomized Pilot Trial of High Dose Vitamin D and Calcium for Bone Health in HIV-Infected Individuals Initiating Highly Active Antiretroviral Therapy (HAART) Social & Scientific Systems, Inc. United States HIV/AIDS
Task Order Agreement No. CRB-DCR01-S-09-00325 Social & Scientific Systems, Inc. United States Drug and Diagnostics Development
Neurological AIDS Research Consortium Washington University in St. Louis United States HIV/AIDS
AIDS Research and Services at SFGH East Bay Community Foundation United States HIV/AIDS
AIDS Clinical Trials Group (ACTG) TTSG Services Social & Scientific Systems, Inc. United States HIV/AIDS
AIDS Clinical Trials Group (ACTG) Community Health Promoter Social & Scientific Systems, Inc. Uganda HIV/AIDS
Supplement to ATCG A5254: Assessing HIV-Related Oral Mucosal Disease and Using Saliva to Measure Viral Load Social & Scientific Systems, Inc. Haiti HIV/AIDS
ACTG A5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects Social & Scientific Systems, Inc. United States HIV/AIDS, Tuberculosis
Clinical Care Response Team Introduction of Antiretroviral Therapy in Elizabeth Glaser Pediatric AIDS Foundation Sites Elizabeth Glaser Pediatric AIDS Foundation Kenya; Uganda; Tanzania; Zimbabwe; South Africa; Ivory Coast HIV/AIDS, Pediatrics
TO#5 ACTG-Clinical Research Site - Community Health Promoter Position Social & Scientific Systems, Inc. United States HIV/AIDS
Task Order # 6: Supplement to SSS A5257 Social & Scientific Systems, Inc. United States HIV/AIDS
Task Order # 7: Supplement to SSS A5254 Social & Scientific Systems, Inc. United States HIV/AIDS, Opportunistic Infection, Oral Health
Task Order # 9: Supplement to SSS A5272 Social & Scientific Systems, Inc. United States HIV/AIDS, Pharmacology and Drug Treatment
Task Order Supplement to A5267 Social & Scientific Systems, Inc. United States HIV/AIDS, Tuberculosis, Pharmacology and Drug Treatment
Clinical Studies of Interactions Between HIV and Malaria NIH National Institute of Allergy and Infectious Disease Uganda HIV/AIDS, Malaria
ADS-TCAD-P0206: TCAD Oral for Treatment of Influenza A Adamas Pharmaceuticals, Inc United States Infectious Disease, HIV/AIDS, Opportunistic Infection, Pharmacology and Drug Treatment
Training in HIV Translational Research NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS, Training and Capacity Building
HIV/TB in Uganda: Punctuated Antiretroviral Therapy University of Georgia Uganda; South Africa HIV/AIDS, Tuberculosis
Clinical Care Response Team Introduction of Antiretroviral Therapy in Elizabeth Glaser Pediatric AIDS Foundation Sites Elizabeth Glaser Pediatric AIDS Foundation Uganda HIV/AIDS, Engagement in Care, Health Systems Strengthening, Training and Capacity Building
HIV/TB in Uganda: Punctuated Antiretroviral Therapy Case Western Reserve University Uganda; South Africa HIV/AIDS, Tuberculosis
Training in HIV Primary Care - Uganda Clinicians Elizabeth Glaser Pediatric AIDS Foundation Uganda HIV/AIDS, Training and Capacity Building
Therapeutic Strategies for HIV Disease NIH National Institute of Allergy and Infectious Disease Uganda HIV/AIDS
Adult AIDS Clinical Trials Unit (AACTU) NIH National Institute of Allergy and Infectious Disease United States HIV/AIDS
UCSF HIV/AIDS Management Training Programs Public Health Institute United States HIV/AIDS, Training and Capacity Building
International AIDS Research and Prevention Pangaea Global AIDS Foundation Uganda HIV/AIDS